The emerging role of cancer nanotechnology in the panorama of sarcoma

Bibliographic Details
Title: The emerging role of cancer nanotechnology in the panorama of sarcoma
Authors: Laura Mercatali, Silvia Vanni, Giacomo Miserocchi, Chiara Liverani, Chiara Spadazzi, Claudia Cocchi, Chiara Calabrese, Lorena Gurrieri, Valentina Fausti, Nada Riva, Damiano Genovese, Enrico Lucarelli, Maria Letizia Focarete, Toni Ibrahim, Luana CalabrĂ², Alessandro De Vita
Source: Frontiers in Bioengineering and Biotechnology, Vol 10 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Biotechnology
Subject Terms: sarcoma, nanotechnology, lipid-based nanocarriers, polymeric nanoparticles, smart materials, Biotechnology, TP248.13-248.65
More Details: In the field of nanomedicine a multitude of nanovectors have been developed for cancer application. In this regard, a less exploited target is represented by connective tissue. Sarcoma lesions encompass a wide range of rare entities of mesenchymal origin affecting connective tissues. The extraordinary diversity and rarity of these mesenchymal tumors is reflected in their classification, grading and management which are still challenging. Although they include more than 70 histologic subtypes, the first line-treatment for advanced and metastatic sarcoma has remained unchanged in the last fifty years, excluding specific histotypes in which targeted therapy has emerged. The role of chemotherapy has not been completely elucidated and the outcomes are still very limited. At the beginning of the century, nano-sized particles clinically approved for other solid lesions were tested in these neoplasms but the results were anecdotal and the clinical benefit was not substantial. Recently, a new nanosystem formulation NBTXR3 for the treatment of sarcoma has landed in a phase 2-3 trial. The preliminary results are encouraging and could open new avenues for research in nanotechnology. This review provides an update on the recent advancements in the field of nanomedicine for sarcoma. In this regard, preclinical evidence especially focusing on the development of smart materials and drug delivery systems will be summarized. Moreover, the sarcoma patient management exploiting nanotechnology products will be summed up. Finally, an overlook on future perspectives will be provided.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2296-4185
Relation: https://www.frontiersin.org/articles/10.3389/fbioe.2022.953555/full; https://doaj.org/toc/2296-4185
DOI: 10.3389/fbioe.2022.953555
Access URL: https://doaj.org/article/f885ba5b521043b3ab3517835c5c98b4
Accession Number: edsdoj.f885ba5b521043b3ab3517835c5c98b4
Database: Directory of Open Access Journals
More Details
ISSN:22964185
DOI:10.3389/fbioe.2022.953555
Published in:Frontiers in Bioengineering and Biotechnology
Language:English